

Review Article

Open Access

Beyond LDL Lowering? Palm Tocotrienols in Cardiometabolic Dyslipidemia: Reconciling Conflicting Lipid Effects with Antioxidant, Anti-Inflammatory and Vascular Actions-A Critical Review

Loso Judijanto

IPOSS, Jakarta, Indonesia

ABSTRACT

Palm-derived tocotrienols have attracted sustained interest as nutraceutical candidates for cardiometabolic disease because experimental studies suggest effects on cholesterol synthesis, oxidative stress, inflammation, endothelial biology, and metabolic signalling. However, the clinical evidence for conventional lipid lowering is substantially less consistent than mechanistic narratives often imply. This critical qualitative literature review examines the apparent discrepancy between biological plausibility and human clinical outcomes. Contemporary randomized evidence does not support a reproducible, clinically substantial reduction in low-density lipoprotein cholesterol, total cholesterol, or triglycerides across populations and formulations, although selected studies report improvements in high-density lipoprotein cholesterol, inflammatory biomarkers, oxidative stress, insulin resistance, or related metabolic endpoints. Interpretation is complicated by heterogeneity in tocotrienol isomers, palm tocotrienol-rich fraction composition, α -tocopherol content, formulation, dose, bioavailability, participant phenotype, background diet, concomitant pharmacotherapy, and outcome selection. We therefore propose a “lipid-centric versus pleiotropic” model. Under the lipid-centric model, current evidence is insufficient to position tocotrienols as alternatives to established LDL-lowering therapy. Under the pleiotropic model, their antioxidant, anti-inflammatory, metabolic, and potentially endothelial actions remain biologically and clinically interesting but require stronger translational validation. Future trials should employ standardized preparations, pharmacokinetic verification, contemporary lipoprotein phenotyping, vascular-function measurements, adequate treatment duration, documented background therapy, and ultimately cardiovascular outcomes.

*Corresponding author

Loso Judijanto, IPOSS, Jakarta, Indonesia. ORCID: <https://orcid.org/0009-0007-7766-0647>.

Received: October 08, 2026; **Accepted:** October 13, 2026; **Published:** October 22, 2026

Keywords: Tocotrienols, Palm Oil, Dyslipidemia, LDL Cholesterol, Triglycerides, HDL Functionality, Oxidative Stress, Inflammation, Endothelial Dysfunction, Cardiovascular Risk

JEL Classification: I10; I12; I18; D81; Q18

Introduction

Cardiometabolic dyslipidemia is no longer adequately described by a single cholesterol concentration. Contemporary cardiovascular prevention distinguishes between the cholesterol content of circulating lipoproteins and the number, composition, metabolic origin, and biological behavior of atherogenic particles. Low-density lipoprotein cholesterol (LDL-C) remains a central therapeutic target because a large body of genetic, epidemiological, mechanistic, and randomized evidence demonstrates a causal relationship between cumulative exposure to LDL-containing apolipoprotein B (apoB) particles and atherosclerotic cardiovascular disease (ASCVD). The magnitude of clinical benefit obtained from lipid-lowering therapies is closely related to the absolute reduction in atherogenic lipoprotein burden and the duration over which that reduction is maintained [1,2,3].

Cardiometabolic risk nevertheless extends beyond LDL-C. Hypertriglyceridemia, triglyceride-rich lipoproteins and their remnants, increased apoB particle number, small dense LDL, lipoprotein(a), dysfunctional high-density lipoprotein (HDL), insulin resistance, inflammation, oxidative stress, endothelial

dysfunction, and prothrombotic signalling can coexist in patients whose LDL-C appears reasonably controlled. The clinical importance of these pathways has stimulated interest in interventions that might modify residual cardiovascular risk without necessarily reproducing the pharmacology of statins or newer LDL-lowering drugs [4,5,6].

Against this background, palm-derived tocotrienols have received substantial scientific and commercial attention. Tocotrienols are members of the vitamin E family and occur as α -, β -, γ , and δ -isomers. Unlike tocopherols, tocotrienols contain an unsaturated isoprenoid side chain, a structural distinction that influences membrane distribution, metabolism, cellular signalling, and potentially antioxidant activity. Palm oil is an important natural source of tocotrienols, commonly delivered experimentally as a tocotrienol-rich fraction (TRF) containing several tocotrienol isomers together with varying amounts of α -tocopherol (Szewczyk, Chojnacka and [7,8,9].

The cardiovascular rationale for tocotrienols has often been constructed around several attractive mechanisms. Experimental observations have suggested regulation of cholesterol biosynthesis, including effects related to 3-hydroxy-3-methylglutaryl-coenzyme A reductase; attenuation of lipid peroxidation; suppression of inflammatory signalling; preservation of endothelial function; modulation of metabolic pathways relevant to insulin resistance; and effects on cellular oxidative balance. A recent cardiovascular-

focused review similarly emphasizes oxidative, inflammatory, lipid-metabolic, endothelial, and insulin-sensitivity pathways, while also noting that adequately powered randomized trials with cardiovascular endpoints are still required [10]. Together, these mechanisms create a biologically plausible argument that tocotrienols could influence multiple components of cardiometabolic disease rather than a single biochemical endpoint [8-11].

Biological plausibility, however, is not equivalent to demonstrated clinical efficacy. The most relevant contemporary meta-analysis of randomized controlled trials evaluating lipid profiles found no statistically consistent overall reduction in total cholesterol, LDL-C, or triglycerides following tocotrienol supplementation, although HDL-C increased and some subgroup patterns were observed [12]. A more recent synthesis specifically examining palm TRF similarly concluded that randomized human studies support potentially beneficial effects on inflammation and lipid peroxidation but that lipid-related findings remain conflicting and require stronger trials [13]. These findings establish the central scientific tension of the present review.

This tension matters because the comparator for a proposed cardioprotective intervention in 2026 is not absence of treatment. Highly effective therapies can produce predictable reductions in LDL-C and cardiovascular events. Statins remain foundational, while ezetimibe, PCSK9-targeting strategies, inclisiran, and bempedoic acid provide additional evidence-based options for appropriate patients. Modern clinical practice therefore provides little justification for presenting a nutraceutical as a substitute for established LDL-lowering therapy merely because it has demonstrated cholesterol-related activity in experimental systems [3-16].

A more useful scientific question is whether tocotrienols affect biological dimensions of cardiometabolic risk that are not captured by LDL-C alone. A compound could theoretically produce little change in conventional LDL-C while influencing lipoprotein oxidation, inflammatory tone, endothelial biology, insulin resistance, or HDL functionality. Conversely, apparently favorable changes in surrogate biomarkers could remain clinically irrelevant if they fail to modify atherogenesis or cardiovascular events. Distinguishing these possibilities requires a framework that separates conventional lipid efficacy from broader pleiotropic biology.

This critical qualitative review therefore evaluates the evidence through two complementary lenses. The first is a lipid-centric model, in which tocotrienols are judged by their effects on LDL-C, apoB-containing particles, triglycerides, remnants, and related atherogenic lipoprotein measures. The second is a pleiotropic model, in which oxidative stress, inflammation, HDL function, endothelial physiology, platelet biology, insulin resistance, and vascular aging are considered independently of major LDL-C lowering. The principal aim is not to establish that tocotrienols are effective or ineffective in a binary sense, but to determine which claims are supported, which remain plausible but unproven, and which require substantially better translational evidence.

Literature Review

Tocotrienol Chemistry, Sources and Biological Identity

Vitamin E comprises four tocopherols and four tocotrienols, each designated α , β , γ , or δ according to methylation patterns on the chromanol ring. Tocopherols contain a saturated phytyl side chain, whereas tocotrienols possess three double bonds within an

unsaturated side chain. This structural difference affects molecular mobility within lipid membranes and contributes to differences in absorption, distribution, metabolism, and biological activity. It is therefore scientifically inappropriate to treat “vitamin E” as a chemically homogeneous intervention [7].

Palm-derived TRF typically contains α -, γ -, and δ -tocotrienol in addition to some α -tocopherol, whereas other natural sources and purified preparations can have substantially different compositions. This distinction becomes crucial when trial findings are compared. Evidence obtained using isolated δ -tocotrienol cannot automatically be generalized to a mixed palm-derived TRF, and findings from a preparation containing a large amount of α -tocopherol may not represent the pharmacological behavior of a tocotrienol-dominant formulation [8,9].

Human bioavailability also presents an important translational constraint. Tocotrienols are lipid-soluble compounds whose gastrointestinal absorption depends on dietary fat, formulation, intestinal processing, lipoprotein transport, and the competitive biology of other vitamin E forms. Pharmacokinetic studies have reported substantial variation according to isomer, administration conditions, dose, and formulation, meaning that nominal oral dose is not equivalent to verified biological exposure [17]. This is a critical methodological issue because an intervention cannot reasonably be judged solely from capsule dose when circulating and tissue exposure is uncertain.

The interaction between tocotrienols and α -tocopherol deserves particular consideration. α -Tocopherol transfer protein favors α -tocopherol, which contributes to its predominant tissue distribution, while tocotrienols have different metabolic and clearance characteristics. Experimental discussions have therefore proposed that substantial α -tocopherol exposure might influence the biological availability or activity of tocotrienols. Although this hypothesis should not be overstated without direct clinical verification, it illustrates why chemical characterization of study preparations is essential [7,17].

Contemporary Cardiometabolic Dyslipidemia

The biological importance of LDL is better understood when LDL-C is interpreted as a proxy rather than the causal entity itself. LDL-C measures the cholesterol mass carried within LDL particles, whereas each LDL particle contains one molecule of apoB. Discordance can therefore occur between cholesterol concentration and atherogenic particle number, particularly in insulin-resistant states characterized by triglyceride enrichment, lipoprotein remodeling, and small dense LDL. ApoB may provide additional information when LDL-C underestimates the number of circulating atherogenic particles [5,18].

Triglycerides likewise require careful interpretation. Triglyceride-rich lipoproteins and their remnants are apoB-containing particles capable of participating in atherogenesis, and triglyceride elevation commonly accompanies diabetes, obesity, hepatic steatosis, and metabolic syndrome. However, pharmacologically lowering triglycerides does not automatically guarantee cardiovascular benefit. The PROMINENT trial, for example, demonstrated that modifying triglyceride-related biomarkers without sufficiently reducing the relevant atherogenic particle burden may fail to translate into fewer cardiovascular events [19]. Similarly, the STRENGTH trial emphasized that apparently favorable biochemical rationale must ultimately be tested against clinical outcomes [20].

Small dense LDL represents another feature of cardiometabolic dyslipidemia. These particles have been associated with increased cardiovascular risk, potentially because of longer plasma residence, oxidative susceptibility, arterial retention, and their close association with insulin resistance and triglyceride-rich metabolism. Nevertheless, because small dense LDL correlates strongly with apoB, triglycerides, and other metabolic abnormalities, it remains important to distinguish its independent causal relevance from its role as a marker of a broader atherogenic phenotype [21-27].

HDL illustrates even more clearly why concentration and function must not be conflated. Epidemiological associations between low HDL-C and cardiovascular disease historically encouraged the assumption that raising HDL-C would be protective. Subsequent pharmacological experience and mechanistic research demonstrated that HDL particle function—including cholesterol efflux, antioxidative capacity, anti-inflammatory properties, endothelial interactions, and protein/lipid composition—may be more informative than HDL-C concentration itself. Therefore, an increase in HDL-C after tocotrienol supplementation should not automatically be presented as evidence of cardiovascular protection [28-32].

Oxidative Stress, Lipid Peroxidation and Atherosclerosis

Oxidative stress is deeply intertwined with vascular biology, but its interpretation is more complex than the concept that antioxidants simply neutralize harmful free radicals. Reactive oxygen species function as physiological signalling molecules at controlled concentrations, while excessive generation or inadequate antioxidant defense can contribute to endothelial dysfunction, lipid oxidation, inflammation, mitochondrial damage, and plaque progression. Important sources include mitochondria, NADPH oxidases, xanthine oxidoreductase, uncoupled nitric oxide synthase, and inflammatory cells [33-36].

Oxidative modification of lipoproteins remains mechanistically relevant to atherosclerosis. Oxidized LDL can influence endothelial activation, macrophage uptake, foam-cell formation, inflammatory signalling, and plaque biology. Small dense LDL may be particularly susceptible to oxidative modification, further linking dyslipidemia with redox biology [24,26,37]. This provides a biologically plausible reason why an intervention might have vascular relevance even if its effect on circulating LDL-C concentration were modest.

Tocotrienols are frequently described as potent lipid-phase antioxidants because their chromanol structure can intercept lipid radicals and their unsaturated side chain may influence membrane distribution. Human palm-TRF studies have generated signals involving lipid peroxidation and oxidative biomarkers, but these effects should be interpreted as mechanistic or surrogate evidence rather than proof of reduced ASCVD. Variability among malondialdehyde, antioxidant-capacity, F2-isoprostane, and related assays also complicates comparison across trials [8,13,38].

Inflammation and Vascular Disease

Atherosclerosis is not simply lipid accumulation; it is a chronic inflammatory process initiated and sustained by interactions among retained apoB-containing lipoproteins, vascular cells, innate immunity, adaptive immunity, and thrombo-inflammatory pathways. Clinical trials targeting inflammatory pathways have demonstrated that inflammation can be therapeutically relevant independently of major LDL-C lowering. The benefit of low-

dose colchicine in chronic coronary disease provides important proof of concept that residual inflammatory risk is clinically actionable, although such evidence cannot be directly extrapolated to nutraceutical antioxidants [39-41].

Tocotrienol research has examined C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor- α (TNF- α), and related inflammatory mediators. The aggregate findings are not uniformly positive. A meta-analysis of randomized trials reported that tocotrienol supplementation did not produce consistent reductions in all inflammatory and oxidative markers, and the apparent CRP benefit was sensitive to the influence of particular trials and intervention types [38]. This reinforces the need to distinguish an isolated positive trial from a reproducible class effect.

At the same time, clinical studies in metabolically abnormal populations suggest that phenotype may influence response. In patients with type 2 diabetes, δ -tocotrienol supplementation was associated with improvements in glycemic control, malondialdehyde, hs-CRP, IL-6, TNF- α , and selected microRNA patterns. In NAFLD, δ -tocotrienol has also been associated with improvements in hepatic or metabolic measures and selected inflammatory biomarkers, although the relevance of these changes to cardiovascular outcomes remains unknown.

Endothelial Function, Vascular Aging and Platelet Biology

Endothelial dysfunction integrates several cardiometabolic insults, including hyperglycemia, atherogenic lipoproteins, oxidative stress, inflammation, hypertension, and insulin resistance. Reduced nitric oxide bioavailability, altered endothelial signalling, leukocyte adhesion, vascular stiffness, and impaired vasodilation may precede clinically apparent ASCVD. Accordingly, vascular-function measurements could provide an important intermediate level of evidence between circulating biomarkers and cardiovascular events.

Vascular aging adds another dimension. Biological vascular aging reflects structural and functional changes including arterial stiffening, endothelial dysfunction, inflammation, oxidative stress, mitochondrial impairment, and cellular senescence. Sirtuin pathways, redox regulation, and metabolic signalling are increasingly recognized as relevant components of this process. Tocotrienols have plausible links to several of these mechanisms, but robust human evidence demonstrating reduced arterial stiffness or slowed vascular aging remains insufficient.

Platelets provide a further interface among inflammation, oxidative stress, and thrombosis. Platelet activation can amplify vascular inflammation and contribute directly to atherothrombotic events. Experimental antioxidant or anti-inflammatory actions of tocotrienols could therefore have theoretical relevance to platelet biology, but the present human literature does not establish a clinically meaningful antithrombotic effect of palm tocotrienols [49,50,54].

Method

Review Design

This article employed a critical qualitative literature review rather than a systematic literature review. The purpose was to synthesize competing interpretations, explain heterogeneity, evaluate mechanistic-to-clinical translation, and construct a conceptual framework for interpreting palm tocotrienol evidence. The review therefore did not claim exhaustive study identification, formal PRISMA-compliant screening, quantitative pooling, or systematic risk-of-bias scoring.

The principal literature window was 2020–2026, consistent with the objective of situating tocotrienol research within contemporary cardiovascular science. Priority was given to randomized clinical trials, meta-analyses, systematic reviews, clinical consensus statements, and high-quality mechanistic reviews published in reputable peer-reviewed journals. Earlier experimental observations were considered conceptually where necessary, but the substantive citation base was concentrated within the contemporary period.

Literature Identification and Thematic Coding

Relevant literature was identified around the terms tocotrienol, palm tocotrienol, tocotrienol-rich fraction, delta-tocotrienol, dyslipidemia, LDL cholesterol, apoB, triglycerides, remnant cholesterol, small dense LDL, HDL function, oxidative stress, oxidized LDL, inflammation, endothelial dysfunction, platelet, metabolic syndrome, diabetes, and NAFLD. Contemporary lipid-lowering and cardiovascular-prevention literature was included to establish the clinical benchmark against which nutraceutical effects should be interpreted.

Evidence was coded into five domains: intervention characteristics, participant phenotype, conventional lipid outcomes, pleiotropic outcomes, and translational relevance. Intervention characteristics included source, isomer composition, α -tocopherol content, dose, formulation, duration, and pharmacokinetic information. Participant characteristics included healthy adults, dyslipidemia, diabetes, metabolic syndrome, insulin resistance, and fatty-liver phenotypes.

Outcome coding distinguished LDL-C, total cholesterol, triglycerides, HDL-C, non-HDL-C, apoB, remnant cholesterol, and lipoprotein characteristics from oxidative, inflammatory, glycemic, vascular, and molecular biomarkers. Cardiovascular events were treated as a separate and substantially higher level of clinical evidence. This distinction was necessary because favorable movement in a biochemical surrogate should not be presented as equivalent to demonstrated cardiovascular risk reduction.

Interpretive Evidence Hierarchy

The qualitative synthesis used a translational hierarchy. Cardiovascular outcome data were considered the highest level of clinically meaningful evidence, followed by adequately powered randomized clinical trials of validated intermediate outcomes. Human mechanistic and biomarker studies were interpreted as supportive but surrogate evidence, whereas cellular and animal findings were used principally to assess mechanistic plausibility.

This framework intentionally prevents a common error in nutraceutical literature: constructing a cardiovascular efficacy claim by combining evidence from fundamentally different levels of inference. A reduction in oxidative biomarkers, an increase in HDL-C, modulation of gene expression, and prevention of myocardial infarction are not interchangeable outcomes. Each supports a different level of scientific conclusion.

Results

Thematic Findings

Theme 1: Conventional Lipid Lowering is Inconsistent

The most important finding of this review is that tocotrienols do not demonstrate a sufficiently consistent effect on conventional lipid parameters to justify being described as established lipid-lowering agents. The meta-analysis by Zuo et al. evaluated randomized controlled trials and found no significant pooled reduction in total cholesterol, LDL-C, or triglycerides, although HDL-C increased

and selected dose-related subgroup effects were reported [12]. This result should anchor interpretation of the clinical literature. The finding does not imply that every individual trial was negative. Nutraceutical studies frequently generate positive results in selected populations, at particular doses, or for individual endpoints. The more important question is whether the magnitude and reproducibility of effect are sufficient to support a clinically generalizable intervention. In the tocotrienol literature, differences in composition, dose, duration, baseline dyslipidemia, sample size, participant phenotype, and background treatment make broad efficacy claims difficult to sustain [9,11].

The 2025 systematic review focused specifically on palm TRF reinforces this interpretation. Across 30 randomized studies involving more than 2,600 participants, the authors identified potentially useful effects in several health domains and highlighted inflammation and lipid peroxidation as promising areas. Importantly, however, they also recognized conflicting lipid findings and the need for more robust trials, standardized doses and formulations, and appropriately selected treatment durations [13].

Recent phenotype-specific randomized evidence further illustrates why pooled estimates can mask context-dependent responses. In a small double-blind trial in chronic kidney disease, tocotrienol-rich fraction supplementation at 300 mg/day for three months was associated with reductions in LDL-C and total cholesterol among participants receiving hemodialysis, whereas the limited sample size and disease-specific setting constrain generalizability [51]. This finding is best interpreted as a signal for targeted replication rather than evidence of uniform lipid-lowering efficacy across cardiometabolic populations.

This distinction is highly relevant clinically. Established lipid-lowering interventions produce effects of a magnitude that is readily detectable and reproducible. Inclisiran, for example, produces substantial LDL-C lowering through sustained PCSK9-directed biology, while bempedoic acid has demonstrated cardiovascular outcome benefit in statin-intolerant patients [14,16]. Tocotrienol studies operate within a very different evidentiary space and should not be compared rhetorically with these agents without acknowledging this difference.

Theme 2: HMG-CoA Reductase Regulation Does Not Equal Statin-Like Clinical Efficacy

One of the most frequently cited rationales for tocotrienols is regulation of HMG-CoA reductase and the mevalonate pathway. Experimental studies have suggested that particular tocotrienol isomers may influence HMG-CoA reductase through mechanisms differing from direct enzymatic inhibition by statins. This mechanistic distinction is scientifically interesting because it suggests that tocotrienols could affect cholesterol homeostasis through regulatory rather than classic competitive pharmacological pathways [9,11].

However, the translation problem is evident. If a biologically meaningful effect on hepatic cholesterol synthesis were strong, sustained, and systemically relevant, one would expect a reasonably reproducible signal in LDL-C or apoB-containing lipoproteins. The inconsistent human LDL-C response suggests that the pathway may be too weak at achievable exposure, highly formulation dependent, compensated by other aspects of cholesterol homeostasis, or important only under particular metabolic conditions.

The distinction between mechanistic activity and therapeutic magnitude is therefore central. Many molecules can modify HMG-CoA reductase expression or cholesterol-related signalling in experimental systems without becoming clinically effective LDL-lowering therapies. The appropriate interpretation is that tocotrienols interact with cholesterol biology, not that they have demonstrated statin-equivalent clinical lipid efficacy.

Theme 3: Triglycerides and Remnant Metabolism Require Better Phenotyping

Triglycerides represent another area in which trial findings are variable. Some studies report reductions, particularly in metabolically abnormal populations, whereas pooled evidence has not demonstrated a consistent overall triglyceride-lowering effect [12]. A trial combining δ -tocotrienol and resveratrol in metabolic syndrome reported improvements in triglycerides and several cardiometabolic biomarkers, but because two biologically active compounds were administered together, the findings cannot establish an isolated tocotrienol effect.

This issue illustrates a broader methodological problem. Serum triglyceride concentration is an imperfect representation of the atherogenic burden carried by triglyceride-rich apoB-containing particles. Contemporary trials should quantify apoB, non-HDL-C, remnant cholesterol, and potentially apoC-III rather than relying only on conventional triglyceride values [5,6,18].

The negative cardiovascular experience with some triglyceride-targeting interventions further emphasizes that biomarker reduction and event reduction are not equivalent. Pemafibrate substantially altered triglyceride-related measures but did not reduce cardiovascular events in the PROMINENT trial [19]. Accordingly, even if a future tocotrienol formulation consistently lowered triglycerides, additional evidence would still be needed before inferring cardiovascular benefit.

Theme 4: HDL-C Increases Should Not Be Overinterpreted

The increase in HDL-C observed in the tocotrienol meta-analysis is potentially interesting but clinically ambiguous [12]. HDL biology is heterogeneous, and raising circulating HDL-C does not necessarily improve macrophage cholesterol efflux, anti-inflammatory activity, antioxidative function, endothelial support, or other potentially protective functions. The field has moved substantially beyond the assumption that HDL-C concentration alone defines the cardiovascular quality of HDL.

A systematic review and meta-analysis evaluating HDL functionality found that measures such as cholesterol efflux and antioxidant or anti-inflammatory capacities carry information relevant to cardiovascular events and mortality that differs from simple HDL-C measurement [27]. Subsequent reviews have emphasized the complexity of cholesterol efflux, HDL remodeling, inflammatory modification, and dysfunctional HDL states [28-31].

This creates a clear research opportunity for tocotrienols. If their antioxidant properties reduce oxidative modification of HDL or preserve specific HDL functions, conventional HDL-C measurements may fail to capture the most biologically relevant effect. Future tocotrienol trials should therefore assess cholesterol efflux capacity, HDL antioxidant function, particle composition, and potentially HDL proteomics rather than treating a small HDL-C increase as proof of cardiovascular benefit [32].

Figure 1 summarizes the central interpretive framework of this review. Tocotrienol exposure should first be understood as a pharmacologically variable intervention because administered dose does not by itself define biological exposure. The model then separates conventional effects on circulating atherogenic lipoproteins from potentially pleiotropic effects on oxidative, inflammatory, metabolic, and vascular pathways.




Figure 1: Lipid-Centric versus Pleiotropic Model of Palm Tocotrienol Action

Figure 1 illustrates that the distinction is important because the evidentiary strength of the two pathways differs. Current randomized evidence provides limited support for a reproducible large LDL-C effect, whereas several studies indicate changes in oxidative, inflammatory, or metabolic biomarkers. The latter findings remain scientifically interesting but occupy a lower level of clinical translation until they are linked to validated vascular endpoints or cardiovascular events [12,13,38].

Theme 5: Oxidative Stress May Be a More Coherent Signal than LDL Lowering

The antioxidant rationale for tocotrienols is stronger mechanistically than the evidence for conventional lipid lowering. Tocotrienols can participate in lipid-phase antioxidant defense and may influence redox-sensitive signalling. Palm TRF trials reviewed in recent literature have shown potentially favorable changes in lipid peroxidation or related oxidative markers, although not uniformly across every biomarker or study population [8,13,38].

The cardiovascular relevance of these observations is plausible because oxidative stress contributes to endothelial dysfunction, inflammatory activation, lipoprotein modification, and plaque biology. NADPH oxidases, mitochondria, xanthine oxidoreductase, and other sources create redox signals that interact with nitric oxide availability and inflammatory pathways [33-36].

Nevertheless, the historical failure of simplistic antioxidant strategies to consistently prevent cardiovascular events warns against assuming that lowering a selected oxidative biomarker necessarily changes disease progression. Oxidative signalling is compartmentalized, context dependent, and partly physiological. A useful tocotrienol trial must therefore demonstrate that changes in redox biology are reproducible, exposure-related, linked to a validated functional endpoint, and not merely statistically significant fluctuations in a nonspecific biomarker.

Oxidized LDL could provide a particularly relevant intermediate endpoint. Because oxidized LDL connects lipoprotein burden with vascular oxidative and inflammatory biology, demonstrating a reproducible reduction in validated oxidized-LDL measures without a major LDL-C change would support the hypothesis that tocotrienols alter lipoprotein quality rather than quantity. Yet assay standardization and prospective linkage to vascular outcomes would remain necessary [37].

Theme 6: Anti-Inflammatory Effects are Promising but Heterogeneous

The anti-inflammatory literature illustrates both the promise and the limitations of tocotrienol research. Khor et al. found that the pooled evidence did not support uniform improvement across inflammatory and oxidative markers. The CRP signal was particularly sensitive to individual study influence, indicating that apparently positive aggregate results may depend on the intervention type or study population rather than representing a robust universal effect [38].

By contrast, selected trials in metabolically abnormal populations have reported substantial biomarker improvements. Mahjabeen et al. found that δ -tocotrienol supplementation in patients with type 2 diabetes improved measures of glycemia, insulin resistance, malondialdehyde, hs-CRP, IL-6, TNF- α , and selected microRNA expression. These data raise the possibility that tocotrienol responsiveness depends on the presence of baseline metabolic and inflammatory disturbance.

A similar pattern has emerged in fatty-liver disease. Pervez et al. reported beneficial effects of δ -tocotrienol on markers related to hepatic steatosis and hepatocellular injury, while a subsequent active-controlled trial found improvements in hepatic steatosis, insulin resistance, and oxidative stress with both δ -tocotrienol and α -tocopherol, with some inflammatory measures showing greater improvement with δ -tocotrienol [52,53]. These findings are clinically interesting because NAFLD/MASLD commonly clusters with atherogenic dyslipidemia and insulin resistance.

However, the trials should not be interpreted as cardiovascular outcome studies. Reductions in IL-6, TNF- α , CRP, or malondialdehyde are intermediate biological observations. The importance of inflammation in ASCVD is supported by cardiovascular trials of established anti-inflammatory strategies, but this does not mean that every intervention lowering an inflammatory biomarker will reduce cardiovascular events [39-41].

Theme 7: Metabolic Phenotype May Determine Responsiveness

A major source of apparent inconsistency in tocotrienol trials may be clinical heterogeneity rather than measurement error alone. Healthy participants with normal lipid concentrations and low inflammatory burden have limited biological room for improvement. By contrast, patients with diabetes, metabolic syndrome, insulin resistance, obesity, or fatty-liver disease may have increased oxidative stress, altered lipoprotein metabolism, endothelial dysfunction, and chronic low-grade inflammation.

This phenotype-dependent model helps reconcile some positive metabolic trials with the weaker pooled lipid evidence. The trial by Mahjabeen et al. involved patients with type 2 diabetes receiving oral glucose-lowering treatment, while the metabolic-syndrome trial by Fatima et al. involved a combination of δ -tocotrienol and resveratrol and found improvement across several risk factors and inflammatory markers [42,43]. A related study reported changes in microRNA patterns following the combination intervention, further suggesting effects on metabolic signalling [44]. A 2025 study of tocotrienol-enriched oat supplementation in metabolic syndrome also reported improvements in aspects of the metabolic profile; however, the food-matrix intervention prevents attribution of those effects to tocotrienol alone [45].

These findings do not prove that tocotrienols should be recommended for diabetes or metabolic syndrome. They instead generate a testable hypothesis that the intervention may have greater biological activity when abnormal metabolic pathways are present. Future trials should therefore pre-specify metabolic phenotypes and examine interaction effects rather than combining healthy individuals and metabolically diseased participants into a single efficacy narrative.

Theme 8: Endothelial and Vascular Evidence Is a Major Missing Link

A persistent weakness in the literature is the limited connection between biochemical changes and validated vascular function. Endothelial dysfunction is an attractive intermediate endpoint because it integrates oxidative stress, inflammation, nitric oxide signalling, insulin resistance, and lipoprotein toxicity. Flow-mediated dilation, pulse-wave velocity, augmentation index, endothelial microparticles, and related measures could therefore provide important translational information [46].

If tocotrienols improve oxidative and inflammatory biology without materially lowering LDL-C, vascular testing could determine whether those effects have functional consequences.

A reproducible improvement in flow-mediated dilation or arterial stiffness, accompanied by confirmed tocotrienol exposure and changes in mechanistically relevant biomarkers, would constitute stronger evidence than biomarker change alone.

Vascular aging also provides a useful conceptual framework because oxidative stress, inflammation, endothelial dysfunction, mitochondrial impairment, and cellular senescence converge in aging arteries. Contemporary literature implicates redox regulation and sirtuin biology in vascular aging and atherosclerosis, but tocotrienol trials have not yet established that supplementation meaningfully modifies these processes in humans [47,48].

Theme 9: Platelet and Atherothrombotic Effects Remain Exploratory

The cardiovascular consequences of atherosclerosis ultimately depend not only on plaque formation but also on plaque disruption and thrombosis. Platelets interact bidirectionally with inflammatory mediators, endothelial cells, leukocytes, and oxidative pathways. Consequently, an intervention affecting redox or inflammatory signalling could theoretically modify platelet activation [49,50].

For tocotrienols, this domain remains underdeveloped clinically. Mechanistic plausibility should not be converted into an antithrombotic claim without controlled human platelet studies and, ultimately, clinical outcome evidence. Future research could examine standardized platelet aggregation, thromboxane-related pathways, platelet-leukocyte aggregates, or other validated measures while carefully monitoring bleeding safety.

This gap is particularly important because the final clinical event in coronary or cerebrovascular disease is often thrombotic. A nutraceutical that affects inflammation but does not alter thrombosis or vascular function may have limited clinical impact. Conversely, a demonstrable effect on platelet biology could broaden the mechanistic framework, but it would require careful validation because platelet inhibition carries both potential benefit and harm [54].

Theme 10: Trial Heterogeneity Is a Biological Problem, Not Merely a Statistical Problem

Tocotrienol trials vary across multiple dimensions simultaneously. Some use mixed palm TRF, others isolated δ -tocotrienol; α -tocopherol content varies; doses differ; treatment periods range substantially; participants have different baseline diseases; and absorption-enhancing formulations are not uniformly used. These variations affect actual biological exposure and therefore undermine direct comparison of nominal dose across studies [13,17].

Background diet represents another potential modifier. Because tocotrienols are lipid soluble, meal composition can affect absorption, while dietary saturated fat, fiber, phytosterols, and other nutrients independently influence lipid profiles. A nutraceutical lipid trial that inadequately records diet may therefore attribute changes to supplementation that partly reflect background dietary behavior.

Concomitant medication is equally important. Participants taking statins, glucose-lowering agents, antihypertensives, or other supplements may have substantially different baseline biology from untreated participants. Statins in particular can create a “floor effect” for LDL-C while simultaneously modifying inflammation and endothelial function. Any attempt to identify a complementary role for tocotrienols therefore requires detailed documentation and stratification of background therapy.

As summarized in Figure 2, apparently conflicting trial outcomes can emerge even if the underlying pharmacology is internally consistent because the term “tocotrienol supplementation” encompasses materially different exposures and clinical contexts. Heterogeneity should therefore be interpreted biologically rather than treated solely as statistical noise.




Figure 2: Sources of Heterogeneity in Human Tocotrienol Trials

Figure 2 also demonstrates why future meta-analyses should avoid assuming interchangeability of purified δ -tocotrienol, mixed palm TRF, and combination interventions. Pharmacokinetic verification is particularly important because dose-response analysis based only on the amount ingested may be misleading when circulating exposure differs substantially across formulations and administration conditions [13,17].

Discussion and Analysis

The Lipid-Centric Interpretation: A High Evidentiary Bar

Under a lipid-centric interpretation, tocotrienols should be assessed using the same fundamental question applied to any therapy proposed for dyslipidemia: does the intervention reproducibly reduce the burden of atherogenic apoB-containing lipoproteins by a magnitude likely to matter clinically? Current evidence does not provide a sufficiently strong affirmative answer.

LDL-containing apoB particles play a causal role in ASCVD, and the relationship between cumulative exposure and disease is well established [1]. Contemporary guidelines therefore emphasize aggressive LDL-C reduction in high-risk patients and the addition of evidence-based nonstatin therapy when required. Against this benchmark, a heterogeneous nutraceutical literature showing little overall LDL-C reduction cannot support therapeutic substitution [1,2,3].

This conclusion should not be interpreted as dismissing tocotrienol biology. Instead, it places the evidence in the correct clinical hierarchy. A compound may possess interesting metabolic or antioxidant properties without being an effective LDL-lowering therapy. The tocotrienol literature becomes more scientifically credible when it accepts this distinction rather than attempting to reinterpret inconsistent LDL results as evidence of equivalent cardiovascular efficacy.

Nutraceuticals can have legitimate roles in prevention, diet-related health, or adjunctive risk management, but they require careful claims. Reviews of nutraceutical approaches to dyslipidemia consistently emphasize differences in evidence quality, formulation, magnitude of effect, regulation, and clinical applicability [55,56]. Palm tocotrienols should be evaluated within that evidence-sensitive framework.

ApoB May Be a Better Future Endpoint Than LDL-C Alone

One explanation sometimes proposed for apparently limited LDL-C changes is that conventional lipid panels may miss changes in lipoprotein composition or particle distribution. This argument is plausible but presently insufficiently tested. If tocotrienols alter particle number, remnant metabolism, or small dense LDL independently of LDL-C concentration, appropriately designed studies should be able to demonstrate those effects.

ApoB is particularly useful because each atherogenic particle contains one apoB molecule, allowing particle burden to be estimated more directly than through cholesterol content. In metabolic syndrome and diabetes, LDL particles may carry less cholesterol per particle, creating discordance between LDL-C and apoB. Future tocotrienol trials should therefore measure apoB routinely alongside LDL-C and non-HDL-C [5,18].

Small dense LDL also merits evaluation, although interpretation should remain cautious because of its strong metabolic correlation with triglyceride-rich lipoproteins and apoB. Reviews consistently identify associations between small dense LDL and cardiovascular risk while also emphasizing methodological and

causal uncertainties [21,22,23,26]. Tocotrienol research could contribute meaningfully by using standardized assays and relating particle changes to verified exposure.

Remnant cholesterol provides another opportunity. Patients with insulin resistance often have increased VLDL and remnant particles even when LDL-C appears acceptable. If tocotrienols primarily influence hepatic triglyceride metabolism rather than LDL receptor pathways, remnant measures might reveal effects not captured by LDL-C. This hypothesis, however, must be demonstrated prospectively rather than inferred retrospectively from mechanistic models [6].

The Pleiotropic Interpretation: More Promising but Less Clinically Proven

The pleiotropic model asks a different question: could tocotrienols modify cardiovascular biology through pathways not requiring substantial LDL-C reduction? This interpretation is supported by experimental and selected human evidence involving oxidative stress, inflammation, insulin resistance, and related pathways, and it is consistent with a recent synthesis focused on diabetes-associated cardiovascular disease [8,10,42,52]. The key limitation is that mechanistic convergence has not yet been matched by adequately powered trials using hard cardiovascular endpoints.

The strongest argument for this model is convergence rather than any single biomarker. Cardiometabolic disease involves reciprocal amplification among oxidative stress, inflammatory activation, endothelial dysfunction, insulin resistance, and abnormal lipoprotein metabolism. A modest intervention affecting several of these nodes could theoretically produce biological benefit even if its LDL-C effect were small.

Yet the evidentiary problem remains. Pleiotropic effects are often easiest to demonstrate at the biomarker level and hardest to validate at the clinical-outcome level. CRP, cytokines, malondialdehyde, antioxidant capacity, and microRNA expression can provide mechanistic insight, but their modification does not establish reduction in myocardial infarction, stroke, or cardiovascular mortality.

The appropriate conclusion is therefore conditional. Tocotrienols may be more scientifically interesting as modifiers of cardiometabolic biology than as conventional cholesterol-lowering agents, but that proposition remains a hypothesis requiring translational validation. This stance avoids both premature rejection and premature clinical advocacy.

The Anti-Inflammatory Signal Must Be Separated from Proven Anti-Inflammatory Cardiovascular Therapy

Inflammation is now an established therapeutic domain in cardiovascular science. Colchicine outcome trials and other mechanistic evidence demonstrate that targeting inflammatory pathways can reduce events in selected populations [39,40]. This makes anti-inflammatory effects of tocotrienols potentially relevant.

However, the existence of an inflammatory mechanism in ASCVD does not validate all anti-inflammatory interventions equally. Drug concentration at relevant tissues, pathway specificity, degree of inflammatory suppression, safety, treatment duration, and patient selection matter. A nutraceutical-induced decline in CRP therefore cannot be equated with an intervention that has demonstrated fewer cardiovascular events.

The tocotrienol meta-analysis by Khor et al. is instructive because it demonstrates heterogeneous biomarker effects and sensitivity to individual studies [38]. This suggests that future research should identify responders mechanistically rather than assume a universal anti-inflammatory effect. Participants with elevated baseline hs-CRP, diabetes, metabolic syndrome, or fatty-liver disease may represent more informative populations.

Oxidative Stress: From Biomarker Reduction to Functional Consequence

The oxidative-stress hypothesis deserves similar caution. Oxidative pathways are involved in endothelial dysfunction, LDL modification, mitochondrial impairment, inflammation, and vascular aging [33,34]. Tocotrienols are biologically suited to interact with lipid-phase oxidative chemistry, making this one of the most plausible areas for further investigation.

The next generation of trials should therefore move beyond generic “total antioxidant capacity” measures. More specific markers of lipid oxidation, oxidized LDL, F2-isoprostanes, redox-sensitive vascular signalling, or validated oxidative damage products could help establish biological specificity. Ideally, biomarker changes should be paired with endothelial-function or imaging endpoints.

This approach would directly address a major translational gap. If a tocotrienol preparation reduces oxidized LDL and improves flow-mediated dilation without appreciably lowering LDL-C, the finding would provide coherent evidence for a non-lipid-quantity mechanism. If oxidative markers change without vascular effects, the clinical interpretation should remain correspondingly limited.

HDL Function Is a High-Priority Research Target

HDL provides perhaps the clearest example of why the lipid-centric and pleiotropic models should interact rather than compete. Tocotrienols may increase HDL-C in some trials, but the clinical significance of this finding cannot be determined without evaluating HDL function. HDL particles perform multiple roles involving cholesterol transport, antioxidative enzymes, endothelial signalling, immunity, and inflammation [29,30].

Cholesterol efflux capacity is among the most extensively studied functional metrics and has been associated with cardiovascular risk in several contexts [27,28]. HDL can also become dysfunctional under oxidative or inflammatory conditions, making its quality particularly relevant in diabetes and metabolic syndrome.

Tocotrienols could theoretically influence HDL function through antioxidant effects even if HDL-C changes only modestly. This hypothesis is attractive because it connects tocotrienol chemistry with contemporary lipoprotein biology. Nevertheless, direct human evidence is needed before the possibility is incorporated into clinical claims.

Figure 3 illustrates why favorable mechanistic observations should not be translated directly into cardiovascular claims. Tocotrienol research contains substantial information at the molecular and biomarker levels, but the evidentiary chain becomes thinner as outcomes move toward vascular function, atherosclerosis progression, and cardiovascular events.




Figure 3: Mechanistic-to-Clinical Translation Gap

Figure 3 Illustrates that this gradient does not invalidate early-stage evidence; rather, it defines what must be demonstrated next. A mature translational program should connect standardized tocotrienol exposure sequentially to mechanistic biomarkers, validated vascular outcomes, and eventually clinical events. Without these links, the cardiovascular significance of pleiotropic effects remains uncertain.

Possible Clinical Phenotypes for Future Research

The most rational future target population may not be patients selected merely for elevated LDL-C. Since established LDL-lowering therapies already perform that task effectively, a tocotrienol trial centered only on moderate LDL-C reduction risks asking a question for which superior therapeutic tools already exist.

Patients with metabolic syndrome could be more informative because they frequently have elevated triglycerides, insulin resistance, inflammatory activation, hepatic steatosis, and small dense LDL. The δ -tocotrienol/resveratrol trial in metabolic syndrome demonstrates the potential responsiveness of this phenotype, although the combination design prevents attribution of effect to tocotrienol alone [43]. Future studies should isolate the intervention or use factorial designs.

Type 2 diabetes is another rational phenotype. The randomized study by Mahjabeen et al. demonstrated simultaneous changes in glycemic, inflammatory, oxidative, and molecular measures [42]. The central question for future trials is whether these improvements reproduce across populations and whether they translate into vascular benefit beyond modern glucose-lowering and lipid-lowering therapies.

MASLD/NAFLD also provides a compelling cardiometabolic setting. Hepatic insulin resistance and abnormal VLDL secretion contribute to atherogenic dyslipidemia, while hepatic inflammation and oxidative stress overlap with systemic cardiometabolic pathways. The δ -tocotrienol studies in fatty-liver disease therefore provide useful mechanistic signals, but trials designed explicitly around cardiovascular and lipoprotein endpoints are still required [52,53].

Tocotrienols Should Be Studied as Adjuncts, Not Replacements

The most clinically credible future positioning is adjunctive. Patients at elevated cardiovascular risk should continue to receive therapies with established outcome benefits. Tocotrienol supplementation, if studied, should be tested on top of appropriate standard care rather than against an artificially untreated comparator when withholding effective therapy would be clinically inappropriate.

This strategy also improves scientific relevance. If tocotrienols provide antioxidant or anti-inflammatory benefits despite well-controlled LDL-C, they could theoretically address residual risk rather than duplicate the primary action of statins. Such a design would directly test the pleiotropic hypothesis.

Background statin therapy must nevertheless be carefully documented because statins themselves influence inflammatory and endothelial pathways. Stratification by statin intensity, baseline LDL-C, apoB, hs-CRP, diabetes status, and metabolic phenotype would therefore be essential. Drug-supplement interactions and safety should also be monitored systematically.

Standardization of the Intervention is Essential

A persistent weakness in nutraceutical research is inadequate characterization of the administered product. For tocotrienols, future reports should quantify α -, β -, γ -, and δ -tocotrienol, α -tocopherol, relevant excipients, oxidation status, and formulation characteristics. The botanical or industrial source should be clearly identified.

Pharmacokinetic verification should become a standard element of high-quality trials. Measurement of plasma tocotrienol isomers would provide an objective marker of adherence and biological exposure, permit exposure-response analysis, and help determine whether apparently negative trials simply failed to achieve adequate systemic concentrations [17].

This would also help resolve the α -tocopherol question. Rather than discussing antagonism theoretically, trials could directly examine whether tocopherol content predicts tocotrienol exposure or outcome response. Such analyses would transform a longstanding mechanistic hypothesis into testable human pharmacology.

Contemporary Biomarkers are Needed

A conventional panel consisting only of total cholesterol, LDL-C, HDL-C, and triglycerides is no longer sufficient for a mechanistically ambitious tocotrienol trial. ApoB and non-HDL-C should be standard. Remnant cholesterol, small dense LDL or particle profiling, Lp(a), and selected apolipoproteins may be included according to the hypothesis [4,5].

HDL functionality is particularly important if HDL-C increase remains a recurring observation. Cholesterol efflux capacity, antioxidant activity, and inflammatory characteristics could determine whether the HDL signal reflects meaningful particle remodeling [27,31].

Oxidative and inflammatory endpoints should likewise be pre-specified rather than selected retrospectively from a large panel. hs-CRP, IL-6, oxidized LDL, F2-isoprostanes, and carefully chosen redox markers could be combined with vascular measures to create a coherent mechanistic chain rather than a collection of statistically significant laboratory changes.

Vascular Function Should Be the Next Translational Step

Before undertaking very large cardiovascular outcome trials, the tocotrienol field needs convincing vascular proof of concept. Flow-mediated dilation provides one option, although methodological standardization is essential. Pulse-wave velocity or other arterial-stiffness measurements could be useful for longer interventions, particularly in older adults or metabolically abnormal patients [46,47].

Imaging endpoints could provide an additional level of evidence. Coronary artery calcium progression, carotid plaque characterization, or other validated measures might be considered for sufficiently long trials, although cost and required sample size would increase substantially.

A successful translational sequence would therefore move from pharmacokinetic verification to molecular biomarkers, lipoprotein function, vascular physiology, imaging, and finally events. This is more scientifically rigorous than repeatedly conducting small studies with conventional lipid panels and inconsistent formulations.

Figure 4 proposes a sequential research architecture capable of resolving the principal weaknesses identified in the current literature. Standardizing the intervention and verifying systemic exposure are necessary before biological non-response can be distinguished from inadequate delivery.




Figure 4: Proposed Future Trial Architecture for Palm Tocotrienols

Figure 4 illustrates that this design also prevents premature claims based on surrogate outcomes. Conventional and advanced lipid phenotyping should be linked to mechanistic biomarkers and subsequently to vascular function. Only after reproducible effects are demonstrated across these intermediate levels should cardiovascular outcome trials be considered.

A Revised Interpretation of the “Conflicting Evidence”

The apparent conflict in tocotrienol research becomes less paradoxical when the evidence is separated by biological level. There is little contradiction between a molecule having antioxidant activity and failing to reduce LDL-C substantially. These are distinct biological functions. Likewise, improvement in insulin resistance or inflammation in metabolically abnormal patients does not require a large effect on cholesterol synthesis.

Some of the conflict therefore arises from asking different studies to answer the same question when they were actually designed to answer different questions. A trial of isolated δ -tocotrienol in type 2 diabetes is not equivalent to a palm-TRF study in healthy volunteers. A study measuring CRP is not a lipid-lowering trial, and a study reporting HDL-C is not necessarily evaluating HDL function.

Another portion of the conflict likely reflects genuine variability in efficacy. Some tocotrienol effects may be small, formulation dependent, or clinically negligible. A critical review should allow that possibility rather than assuming every negative trial reflects flawed design.

The most defensible synthesis is therefore neither that “tocotrienols lower cholesterol” nor that “tocotrienols do not work.” Current evidence indicates that conventional LDL-lowering efficacy is weak and inconsistent, while selected pleiotropic and metabolic effects remain credible enough to justify better-designed translational research.

Critical Implications for Cardiometabolic Practice and Research

The clinical interpretation of this literature should begin with what is already known rather than with what is hoped. LDL-C and apoB-containing particles remain foundational targets in cardiovascular prevention. Patients who meet indications for pharmacological lipid lowering should receive therapies supported by cardiovascular outcome evidence, and tocotrienol supplementation should not be presented as a replacement for those therapies [1,2,3].

This point is particularly important in the context of statin intolerance. Statin-associated symptoms can complicate treatment, but contemporary recommendations emphasize careful evaluation, rechallenge when appropriate, dose adjustment, alternative statins, and evidence-based nonstatin therapy rather than abandonment of LDL reduction. Bempedoic acid and PCSK9-directed approaches further expand treatment options [14,15,16].

The more credible research niche for tocotrienols lies in residual metabolic, oxidative, or inflammatory risk. This possibility is consistent with the metabolic studies reviewed above and with modern recognition that ASCVD reflects more than circulating LDL-C alone. However, “residual risk” should not become a vague justification for any favorable biomarker. Each proposed pathway must be independently validated.

A second implication concerns the distinction between nutraceutical use and pharmacological evidence. Dietary compounds can influence health without meeting the evidentiary requirements of prescription drugs. Problems arise when mechanistic language is used to imply clinical efficacy that has not been demonstrated. A scientifically responsible tocotrienol literature should be comfortable describing an intervention as promising for selected pathways while acknowledging that hard cardiovascular benefit remains unproven [55-57].

Third, publication and interpretation practices should account for multiplicity. Small nutraceutical trials often measure numerous biomarkers, creating opportunities for chance-positive findings. Pre-registration of primary and secondary endpoints, adjustment for multiple comparisons where appropriate, transparent reporting of null findings, and publication of negative studies would improve the reliability of the evidence base.

Fourth, the field should distinguish palm-derived TRF from purified tocotrienol isomers. Palm TRF is clinically and commercially relevant, but its mixture of compounds means that outcomes cannot be attributed automatically to a single isomer. Conversely, an isolated δ -tocotrienol trial may provide useful pharmacological information without representing the effect of palm TRF. Both research streams are valuable if their boundaries are respected.

Finally, long-term safety, adherence, and interactions with standard therapy deserve more attention. Tocotrienols are generally regarded as well tolerated in studied doses, but cardiovascular prevention may involve years of treatment and extensive polypharmacy. A supplementation strategy intended for long-term adjunctive use requires a correspondingly long-term understanding of safety.

Conclusion

Palm-derived tocotrienols occupy an unusual position in cardiometabolic science. Their mechanistic profile is broad and biologically attractive, encompassing cholesterol-related pathways, oxidative stress, inflammation, metabolic signalling, lipid peroxidation, and potentially vascular biology. Yet the strongest available human evidence does not demonstrate a reproducible, clinically substantial reduction in LDL-C, total cholesterol, or triglycerides across interventions and populations.

This discrepancy should not be resolved by selectively emphasizing positive findings. Under a lipid-centric model, tocotrienols remain insufficiently supported as conventional lipid-lowering therapies and should not be positioned as replacements for statins or other evidence-based LDL-lowering interventions. Under a pleiotropic model, however, selected human studies provide credible signals involving inflammatory, oxidative, glycemic, hepatic, and cardiometabolic biomarkers.

The central unresolved question is whether these pleiotropic effects meaningfully alter vascular biology and cardiovascular outcomes. Answering it requires a new generation of trials using chemically standardized palm-derived preparations, verified pharmacokinetic exposure, appropriate metabolic phenotyping, apoB and remnant

measurements, HDL functional assays, validated oxidative and inflammatory biomarkers, vascular-function testing, adequate duration, and transparent documentation of background therapy.

The most productive future narrative is therefore not that tocotrienols are an alternative route to conventional cholesterol lowering. Rather, they should be investigated as potential adjunctive modulators of residual cardiometabolic biology. Their clinical value will ultimately depend not on the elegance of their molecular mechanisms, but on whether those mechanisms produce reproducible improvements in vascular function and, eventually, patient-important cardiovascular outcomes.

References

1. Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, et al. (2020) Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights, *European Heart Journal* 41: 2313-2330.
2. Visseren FLJ (2021) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice, *European Heart Journal* 42: 3227-3337.
3. Lloyd-Jones DM, et al. (2022) 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk, *Journal of the American College of Cardiology* 80: 1366-1418.
4. Kronenberg F (2022) Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement, *European Heart Journal* 43: 3925-3946.
5. Mehta A, Shapiro MD (2022) Apolipoproteins in vascular biology and atherosclerotic disease, *Nature Reviews Cardiology* 19: 168-179.
6. Wang K, Wang R, Yang J (2022) Remnant cholesterol and atherosclerotic cardiovascular disease: metabolism, mechanism, evidence, and treatment, *Frontiers in Cardiovascular Medicine* 9: 913869.
7. Szweczyk K, Chojnacka A, Górnicka M (2021) Tocopherols and tocotrienols—bioactive dietary compounds; what is certain, what is doubt?, *International Journal of Molecular Sciences* 22: 6222.
8. Zainal Z, Khaza'ai H, Radhakrishnan AK, Chang SK (2022) Therapeutic potential of palm oil vitamin E-derived tocotrienols in inflammation and chronic diseases: evidence from preclinical and clinical studies, *Food Research International* 156: 111175.
9. Ranasinghe R, Mathai M, Zulli A (2022) Revisiting the therapeutic potential of tocotrienol, *BioFactors* 48: 813-856.
10. Ali M, Sheikh Abdul Kadir SH, Ibrahim E, Albaraikan A (2026) Tocotrienol-rich fraction of vitamin E in diabetes and cardiovascular disease: from molecular mechanisms to clinical application, *International Journal of Cardiology Cardiovascular Risk and Prevention* 30: 200686.
11. Wong SK (2020) Potential role of tocotrienols on non-communicable diseases: a review of current evidence, *Nutrients* 12: 259.
12. Zuo S, Wang G, Han Q, Xiao H, Santos HO, et al. (2020) The effects of tocotrienol supplementation on lipid profile: a meta-analysis of randomized controlled trials, *Complementary Therapies in Medicine* 52: 102450.
13. Looi AD, Palanisamy UD, Moorthy M, Radhakrishnan AK (2025) Health benefits of palm tocotrienol-rich fraction: a systematic review of randomized controlled trials, *Nutrition Reviews* 83: 307-328.
14. Ray KK (2020) Two phase 3 trials of inclisiran in patients

- with elevated LDL cholesterol, *New England Journal of Medicine* 382: 1507-1519.
15. Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, et al. (2022) NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient, *Journal of Clinical Lipidology* 16: 361-375.
16. Nissen SE (2023) Bempedoic acid and cardiovascular outcomes in statin-intolerant patients, *New England Journal of Medicine* 388: 1353-1364.
17. Sharif M, Khan DA, Farhat K, Noor M, Khan MA, et al. (2023) Pharmacokinetics and bioavailability of tocotrienols in healthy human volunteers: a systematic review, *Journal of the Pakistan Medical Association* 73: 603-610.
18. Glavinovic T, Thanassoulis G, de Graaf J, Couture P, Hegele RA, et al. (2022) Physiological bases for the superiority of apolipoprotein B over low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as a marker of cardiovascular risk, *Journal of the American Heart Association* 11: e025858.
19. Das Pradhan A, Glynn RJ, Fruchart J-C (2022) Triglyceride lowering with pemafibrate to reduce cardiovascular risk, *New England Journal of Medicine* 387: 1923-1934.
20. Nicholls SJ (2020) Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial, *JAMA* 324: 2268-2280.
21. Liou L, Kaptoge S (2020) Association of small, dense LDL-cholesterol concentration and lipoprotein particle characteristics with coronary heart disease: a systematic review and meta-analysis, *PLOS ONE* 15: e0241993.
22. Santos HO, Earnest CP, Tinsley GM, Izidoro LFM, Macedo RCO (2020) Small dense low-density lipoprotein-cholesterol: analysis, effects on cardiovascular endpoints and dietary strategies, *Progress in Cardiovascular Diseases* 63: 503-509.
23. Kanonidou C (2021) Small dense low-density lipoprotein: analytical review, *Clinica Chimica Acta* 520: 172-178.
24. Rizvi AA, Stoian AP, Janez A, Rizzo M (2021) Lipoproteins and cardiovascular disease: an update on the clinical significance of atherogenic small, dense LDL and new therapeutical options, *Biomedicines* 9: 1579.
25. Jin X, Yang S, Lu J, Wu M (2022) Small, dense low-density lipoprotein-cholesterol and atherosclerosis: relationship and therapeutic strategies, *Frontiers in Cardiovascular Medicine* 8: 804214.
26. Krauss RM (2022) Small dense low-density lipoprotein particles: clinically relevant?, *Current Opinion in Lipidology* 33: 160-166.
27. Soria-Flrido MT, Schröder H, Grau M, Fitó M, Lassale C (2020) High density lipoprotein functionality and cardiovascular events and mortality: a systematic review and meta-analysis, *Atherosclerosis* 302: 36-42.
28. Hafiane A, Favari E, Daskalopoulou SS, Vuilleumier N, Frias MA (2020) High-density lipoprotein cholesterol efflux capacity and cardiovascular risk in autoimmune and non-autoimmune diseases, *Metabolism* 104: 154141.
29. Pownall HJ, Rosales C, Gillard BK (2021) High-density lipoproteins, reverse cholesterol transport and atherogenesis, *Nature Reviews Cardiology* 18: 712-723.
30. Endo Y, Fujita M, Ikewaki K (2023) HDL functions-current status and future perspectives, *Biomolecules* 13: 105.
31. Linton MF, Yancey PG, Tao H, Davies SS (2023) HDL function and atherosclerosis: reactive dicarbonyls as promising targets of therapy, *Circulation Research* 132: 1521-1545.
32. Madaudo C (2024) Dysfunctional high-density lipoprotein cholesterol and coronary artery disease: a narrative review, *Journal of Personalized Medicine* 14: 996.
33. Dubois-Deruy E, Peugnet V, Turkieh A, Pinet F (2020) Oxidative stress in cardiovascular diseases, *Antioxidants* 9: 864.
34. Daiber A, Hahad O, Andreadou I, Steven S, Daub S, et al. (2021) Redox-related biomarkers in human cardiovascular disease-classical footprints and beyond, *Redox Biology* 42: 101875.
35. Polito L, Bortolotti M, Battelli MG, Bolognesi A (2021) Xanthine oxidoreductase: a leading actor in cardiovascular disease drama, *Redox Biology* 48: 102195.
36. Sylvester AL, Zhang DX, Ran S, Zinkevich NS (2022) Inhibiting NADPH oxidases to target vascular and other pathologies: an update on recent experimental and clinical studies, *Biomolecules* 12: 823.
37. Khatana C, Saini NK, Chakrabarti S, Saini V, Sharma A, et al. (2020) Mechanistic insights into the oxidized low-density lipoprotein-induced atherosclerosis, *Oxidative Medicine and Cellular Longevity* 2020: 5245308.
38. Khor B-H, Tiong H-C, Tan SC, Wong SK, Chin K-Y, et al. (2021) Effects of tocotrienols supplementation on markers of inflammation and oxidative stress: a systematic review and meta-analysis of randomized controlled trials, *PLOS ONE* 16: e0255205.
39. Nidorf SM (2020) Colechicine in patients with chronic coronary disease, *New England Journal of Medicine* 383: 1838-1847.
40. Soehnlein O, Libby P (2021) Targeting inflammation in atherosclerosis—from experimental insights to the clinic, *Nature Reviews Drug Discovery* 20: 589-610.
41. Engelen SE, Robinson AJB, Zurke YX, Monaco C (2022) Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?, *Nature Reviews Cardiology* 19: 522-542.
42. Mahjabeen W, Khan DA, Mirza SA, Pervez MA (2021) Effects of delta-tocotrienol supplementation on glycemic control, oxidative stress, inflammatory biomarkers and miRNA expression in type 2 diabetes mellitus: a randomized control trial, *Phytotherapy Research* 35: 3968-3976.
43. Fatima S, Khan DA, Aamir M, Pervez MA, Fatima F (2023a) δ -Tocotrienol in combination with resveratrol improves the cardiometabolic risk factors and biomarkers in patients with metabolic syndrome: a randomized controlled trial, *Metabolic Syndrome and Related Disorders* 21: 25-34.
44. Fatima S, Khan DA, Fatima F, Aamir M, Ijaz A, et al. (2023b) Role of δ -tocotrienol and resveratrol supplementation in the regulation of microRNAs in patients with metabolic syndrome: a randomized controlled trial, *Complementary Therapies in Medicine* 74: 102950.
45. Norazman CW, Mohd Sopian M, Lee LK (2025) Effects of tocotrienol-enriched oat supplementation on metabolic profile, nutritional status and health-related quality of life among patients with metabolic syndrome, *Food & Function* 16: 1847-1863.
46. Xu S, Ilyas I, Little PJ, Li H, Kamato D, et al. (2021) Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies, *Pharmacological Reviews* 73: 924-967.
47. Gopcevic KR (2021) Pathophysiology of circulating biomarkers and relationship with vascular aging, *Frontiers in Physiology* 12: 789690.
48. Grootaert MOJ, Bennett MR (2022) Sirtuins in atherosclerosis:

- guardians of healthspan and therapeutic targets, *Nature Reviews Cardiology* 19: 668-683.
49. Lordan R, Tsoupras A, Zabetakis I (2021) Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: potential role of antiplatelet agents, *Blood Reviews* 45: 100694.
 50. Theofilis P (2021) Inflammatory mediators of platelet activation: focus on atherosclerosis and COVID-19, *International Journal of Molecular Sciences* 22: 11170.
 51. Trugilho L, Alvarenga L, Cardozo L, Paiva B, Brito J, et al. (2025) Effects of tocotrienol on cardiovascular risk markers in patients with chronic kidney disease: a randomized controlled trial, *Journal of Nutrition and Metabolism* 2025: 8482883.
 52. Pervez MA, Khan DA, Slehria AUR, Ijaz A (2020) Delta-tocotrienol supplementation improves biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial, *Complementary Therapies in Medicine* 52: 102494.
 53. Pervez MA, Khan DA, Mirza SA, Slehria AUR, Nisar U, et al. (2022) Comparison of delta-tocotrienol and alpha-tocopherol effects on hepatic steatosis and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: a randomized double-blind active-controlled trial, *Complementary Therapies in Medicine* 70: 102866.
 54. Cimmino G, Di Serafino L, Cirillo P (2023) Evolving concepts in the pathophysiology of atherosclerosis: from endothelial dysfunction to thrombus formation through multiple shades of inflammation, *Journal of Cardiovascular Medicine* 24: e156-e167.
 55. Penson PE, Banach M (2021) Nutraceuticals for the control of dyslipidaemias in clinical practice, *Nutrients* 13: 2957.
 56. Cicero AFG, Fogacci F, Stoian AP, et al. (2021) Nutraceuticals in the management of dyslipidemia: which, when, and for whom?, *Current Atherosclerosis Reports* 23: 57.
 57. Superko H, Garrett B (2022) Small dense LDL: scientific background, clinical relevance, and recent evidence still a risk even with “normal” LDL-C levels, *Biomedicines* 10: 829.

Copyright: ©2026 Loso Judijanto. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.